T Eisen

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. pmc Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin
    Tim Eisen
    Cambridge University Health Partners, Addenbrooke s Hospital, Cambridge, UK
    Curr Oncol Rep 16:370. 2014
  2. doi request reprint Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
    Tim Eisen
    Cambridge University Health Partners, Cambridge, UK
    Lancet Oncol 13:1055-62. 2012
  3. pmc Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
    B P Fairfax
    Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
    BMC Cancer 12:590. 2012
  4. pmc Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
    T Eisen
    Department of Oncology R4, Cambridge Biomedical Research Centre, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Br J Cancer 105:353-9. 2011

Collaborators

Detail Information

Publications4

  1. pmc Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin
    Tim Eisen
    Cambridge University Health Partners, Addenbrooke s Hospital, Cambridge, UK
    Curr Oncol Rep 16:370. 2014
    ..Naptumomab estafenatox has been clinically tested in a range of solid tumors with focus on renal cell carcinoma. This review looks at the clinical experience with the new immunotoxin and its potential...
  2. doi request reprint Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
    Tim Eisen
    Cambridge University Health Partners, Cambridge, UK
    Lancet Oncol 13:1055-62. 2012
    ..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
  3. pmc Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
    B P Fairfax
    Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
    BMC Cancer 12:590. 2012
    ..The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort...
  4. pmc Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
    T Eisen
    Department of Oncology R4, Cambridge Biomedical Research Centre, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, UK
    Br J Cancer 105:353-9. 2011
    ....